Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

被引:503
作者
Ansell, BJ [1 ]
Navab, M [1 ]
Hama, S [1 ]
Kamranpour, N [1 ]
Fonarow, G [1 ]
Hough, G [1 ]
Rahmani, S [1 ]
Mottahedeh, R [1 ]
Dave, R [1 ]
Reddy, ST [1 ]
Fogelman, AM [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA
关键词
D O I
10.1161/01.CIR.0000103624.14436.4B
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The inflammatory/antiinflammatory properties of HDL were compared with HDL cholesterol in 2 groups of patients and in age- and sex-matched control subjects. Methods and Results-Group 1 consisted of 26 patients not yet taking a statin who presented with coronary heart disease (CHD) or CHD equivalents by National Cholesterol Education Program Adult Treatment Panel III criteria studied before and 6 weeks after 40 mg/d of simvastatin. Group 2 consisted of 20 patients with documented CHD and HDL cholesterol greater than or equal to84 mg/dL. The inflammatory/antiinflammatory properties of HDL were determined by the ability of the subject's HDL to alter LDL-induced monocyte chemotactic activity (MCA) in a human artery wall coculture. Induction of MCA by a control LDL was determined in the absence or presence of the subject's HDL. Values in the absence of HDL were normalized to 1.0. Values >1.0 after the addition of HDL indicated proinflammatory HDL; values <1.0 indicated antiinflammatory HDL. Group 1 values before simvastatin were LDL cholesterol, 118+/-24 mg/dL; HDL cholesterol, 57+/-13 mg/dL; triglycerides, 125+/-64 mg/dL; and high-sensitivity C-reactive protein (hs-CRP), 1.7+/-1.9 mg/L; and MCA values were 1.38+/-0.91, compared with 0.38+/-0.14 for control subjects (P=1.5x10(-5)). After simvastatin, values were LDL cholesterol, 73+/-24 mg/dL; HDL cholesterol, 61+/-14 mg/dL; triglycerides, 99+/-52 mg/dL; and hs-CRP, 1.3+/-1.3 mg/L; and MCA values were 1.08+/-0.71. In group 2, values were LDL cholesterol, 108+/-34 mg/dL; HDL cholesterol, 95+/-14 mg/dL; triglycerides, 89+/-44 mg/dL; and hs-CRP, 0.8+/-0.7 mg/L; and MCA values were 1.28+/-0.29, compared with 0.35+/-0.11 for control subjects (P=1.7x10(-14)). Similar results were obtained with the cell-free assay. Conclusions-The inflammatory/antiinflammatory properties of HDL distinguished patients from control subjects better than HDL cholesterol and were improved with simvastatin.
引用
收藏
页码:2751 / 2756
页数:6
相关论文
共 23 条
  • [1] HIGH-DENSITY-LIPOPROTEIN IS THE MAJOR CARRIER OF LIPID HYDROPEROXIDES IN HUMAN BLOOD-PLASMA FROM FASTING DONORS
    BOWRY, VW
    STANLEY, KK
    STOCKER, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) : 10316 - 10320
  • [2] INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY
    CASTELLI, WP
    GARRISON, RJ
    WILSON, PWF
    ABBOTT, RD
    KALOUSDIAN, S
    KANNEL, WB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20): : 2835 - 2838
  • [3] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [4] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS
    Downs, JR
    Clearfield, M
    Weis, S
    Whitney, E
    Shapiro, DR
    Beere, PA
    Langendorfer, A
    Stein, EA
    Kruyer, W
    Gotto, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20): : 1615 - 1622
  • [5] Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation
    Gabay, C
    Kushner, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) : 448 - 454
  • [6] HIGH-DENSITY LIPOPROTEIN AS A PROTECTIVE FACTOR AGAINST CORONARY HEART-DISEASE - FRAMINGHAM STUDY
    GORDON, T
    CASTELLI, WP
    HJORTLAND, MC
    KANNEL, WB
    DAWBER, TR
    [J]. AMERICAN JOURNAL OF MEDICINE, 1977, 62 (05) : 707 - 714
  • [7] Kwiterovich PO, 1998, AM J CARDIOL, V82, p13Q
  • [8] Mildly oxidized LDL induces an increased apolipoprotein J paraoxonase ratio
    Navab, M
    HamaLevy, S
    VanLenten, BJ
    Fonarow, GC
    Cardinez, CJ
    Castellani, LW
    Brennan, ML
    Lusis, AJ
    Fogelman, AM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (08) : 2005 - 2019
  • [9] Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
    Navab, M
    Anantharamaiah, GM
    Hama, S
    Garber, DW
    Chaddha, M
    Hough, G
    Lallone, R
    Fogelman, AM
    [J]. CIRCULATION, 2002, 105 (03) : 290 - 292
  • [10] Navab M, 2001, J LIPID RES, V42, P1308